UTHR vs ZYME · P/E 20, rev $2.88B vs rev $76.3M
United Therapeutics Corporation (UTHR) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported UTHR revenue for 2024-12-31 was $2.88B. Net income was $1.20B. Revenue was up 23.6% from 2023-12-31 to 2024-12-31. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
UTHR currently screens at market cap $23.41B and trailing P/E 20.4. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the UTHR and ZYME stock pages for the full models.
Not investment advice.